Reconsidering Aromatase for Breast Cancer Treatment: New Roles for an Old Target

Abstract

The current therapeutic approach for the treatment of hormone dependent breast cancer includes interference with estrogen receptors via either selective modulators or estrogens deprivation, by preventing their biosynthesis with aromatase inhibitors. Severe side effects and acquired resistance are drawbacks of both drug classes, and the efforts to overcome these issues still allow for research in this field to be animated. This review reports on recent findings that have opened new avenues for reconsidering the role of aromatase enzymes (and estrogen receptors) leading to the possibility of looking at well-known targets in a new perspective.

Keywords

• aromatase
• aromatase inhibitors
• allosteric modulation
• breast cancer
• drug development
• multitarget